Workforce Drug Testing Positivity Climbed to Highest Rate in 16 Years, New Quest Diagnostics Drug Testing Index™ Analysis Finds

Prnewswire | August 25, 2020

The rate of workforce drug positivity hit a sixteen-year high in 2019, according to a new analysis released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Positivity rates in the combined U.S. workforce increased in urine drug tests, climbing to the highest level since 2003 (4.5%) and more than 28% percent higher than the thirty-year low of 3.5 percent recorded between 2010 and 2012. In addition to overall increases in workforce drug positives, specific regions of the United States, particularly the Midwest, experienced dramatic increases in positivity for cocaine and methamphetamine as well as marijuana.

Spotlight

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Spotlight

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Related News

Jazz Pharmaceuticals Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies

Jazz Pharmaceuticals | September 09, 2020

Jazz Pharmaceuticals plc today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX) to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway. This research collaboration follows the previously announced sale of Redx's pre-clinical pan-RAF inhibitor program to Jazz for the potential treatment of Raf and Ras mutant tumors in July 2019. Under the terms of the research collaboration agreement, Jazz will make an upfront payment to Redx of $10 million followed by another $10 million in year two, provided research work is continuing. Following delivery of an IND-ready molecule, Redx will be eligible to receive up to a further $200 million from Jazz in development, regulatory and commercial milestone payments for each program

Read More

RESEARCH

Biognosys Launches Next-Generation Blood Biomarker Discovery Solution

Biognosys | November 10, 2021

Biognosys, a leader in proteomics solutions for drug discovery and development, announces the launch of its next-generation blood biomarker discovery solution, which will be offered as a contract research service. The service is designed to help researchers decipher the complexity of the blood proteome and unlock unbiased discoveries for pharma and diagnostics development and precision medicine. The launch will feature a series of events and resources that detail the science and technology behind the new solution, as well as its applications Launch webinar on November 9, entitled: “Plasma Proteomics: The Next Frontier of Biomarker Discovery in the Precision Medicine Era.” Presentation and exhibition at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12-14 in Washington, D.C. The new service offers unprecedented depth, quantitative precision, and throughput for discovery research. The solution will search the complete plasma proteome to quantify up to 3,000 of the most relevant proteins and measure tens of thousands of peptide-level datapoints to provide a deep understanding of key disease pathways. The solution can be applied across all biological species and to any other biofluid, such as cerebrospinal fluid or urine. In addition to the biofluid biomarker discovery service, an improved tissue biomarker discovery service is available, offering an industry-leading depth of 10,000 proteins. Both solutions are based on Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM™) technology and its optimized Liquid Chromatography - Mass Spectrometry (LC-MS) workflow. The clinical transferability of this technology allows quick transition from early stage discovery to specific, targeted panels that can be applied in a regulated setting. Kanna Palaniappan, PhD, Staff Scientist at Freenome, a company that develops blood tests for early cancer detection, powered by a multi-omics platform, testifies: “We have used Biognosys’ services for a number of biomarker discovery studies focused on improving cancer detection, taking advantage of their constantly improving platform, and their ability to run large-scale studies while maintaining high data quality. We have had a valuable and productive relationship and we look forward to future collaborations.” “We are thrilled to offer customers our innovative, next-generation biomarker discovery solution and enable them to gain biological insights beyond what pre-defined panels can provide. By diving deep into the plasma proteome with an unbiased view, we profile the proteins that are of highest relevance to our customer’s disease areas of focus. This is what we call true discovery.” Kristina Beeler, PhD, Chief Business Officer of Biognosys Lukas Reiter, PhD, Chief Technology Officer of Biognosys states: “Mass spectrometry-based proteomics is the ideal tool to explore the blood proteome in an unbiased manner. Our continuous R&D improvements have enabled us to reach an unprecedented depth to quantify the very low abundant protein ranges that are of highest biological significance, while ensuring high scalability for clinical research.” About Biognosys Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research.

Read More

BUSINESS INSIGHTS

CEM Corporation and AmbioPharm enter into US partnership for GMP peptide production

CEM Corporation | September 16, 2021

CEM Corporation and AmbioPharm, Inc. are pleased to announce the formation of a partnership to produce GMP peptides for the global market. The partnership includes the exclusive 1Use of CEM's microwave peptide synthesis technology on a large scale for the production of GMP peptides up to several kilograms using its own scalable reactors. The main advantages of this new relationship are the extremely short production times, the ability to efficiently produce more difficult peptide sequences, and the ability to incorporate green chemistry protocols. This partnership will enable the rapid and efficient production of new chemical peptide entities (NCEs) using the latest available technologies. With this agreement, AmbioPharm has started peptide synthesis at its North Augusta facility to better serve customers with fast microwave synthesis processes. CEM's peptide production technology utilizes automated, large-scale microwave solid phase peptide synthesis systems (SPPS) that have been proven to improve peptide purity and minimize excess reagents. In addition, the CEM has developed proprietary coupling methods optimized for reactions at elevated temperatures 2 , a unique way to combine the coupling and deprotection reactions in a single step 3 , and established the use of more environmentally friendly solvents that are more accessible at elevated temperatures 4 . These unique technological advantages are licensed to AmbioPharm for GMP production. AmbioPharm is a recognized leader in cGMP peptide production. The company employs more than 675 people and recently completed a major expansion of its headquarters in South Carolina, USA, adding nearly 56,000 square feet of additional peptide manufacturing capacity. The production plant has a cleaning capacity of up to 30 kg / batch and a freeze-drying capacity of up to 1,000 liters. The CEM Liberty Pro Synthesizer offers different reactor sizes (3, 8 and 15 liters) that allow the synthesis of batches from 5 g to 500 g of the final peptide. Peptide-based drugs have enormous potential for the future and we are pleased to be able to help improve their production process. AmbioPharm is an ideal partner and we believe this relationship will enhance the opportunities for the manufacturing of peptide therapeutics. - Michael J. Collins, Ph.D., President and CEO of CEM Corporation. With the addition of CEM's microwave technology to our GMP peptide manufacturing options, we can offer even better service in terms of faster delivery for our partners' products and unique opportunities to make longer and more complex peptides accessible using microwave methods. - Chris Bai, Ph.D., CEO of AmbioPharm Inc. About CEM CEM Corporation, a privately held company based in Matthews, North Carolina, is a leading provider of laboratory instruments. The company has subsidiaries in the UK, Germany, Italy, France, Japan and Singapore and a worldwide network of distributors. CEM designs and manufactures systems for life sciences, analytical laboratories and processing plants worldwide. The company's products are used in many industries, including the pharmaceutical, biotech, chemical and food industries, as well as academic research. About AmbioPharm, Inc . AmbioPharm, part of the Ambio Pharmaceuticals Group, is a leading, innovation-driven company that specializes in the development and manufacture of peptides and peptide-like products. AmbioPharm offers a comprehensive range of services and produces customized products for research, clinical development and commercial use for pharmaceutical and biotechnology companies worldwide. AmbioPharm operates internationally, has its headquarters in the USA, locations in Europe, the USA and Asia and has more than 14 years of experience and expertise.

Read More